Palvella Therapeutics, Inc.
- PVLA
- NASDAQ
- Biotechnology
- Rare Skin Disease Drugs
- Clinical-Stage Biopharma
$123.67
Today +2.80%Quote Oct 19, 2026, 05:00 PM UTC
−22.05%over the last month
Max drawdown −23.9%From 1-month high −23.9%3 months −3.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
29
Market value
$1.78B
Quote Oct 19
Floor
$120.33
2.7% below price
Resistance
$128.89
4.2% above price
Price vs analyst targets
11 analysts
Lowest target
$207.00Highest target
$246.00
$207.00Highest target
$246.00
- Price $123.67
- Average target $228.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 85% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PVLAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free